FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Company

Click Therapeutics

Pharmaceutical intelligence for Click Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalAugust 11, 2026

Click Therapeutics initiates OLE study for digital therapeutic in schizophrenia

Click Therapeutics has initiated an open label extension study to evaluate the maintained efficacy and safety of a second consecutive course of its digital therapeutic, the Click Therapeutics Study App, as an adjunct treatment to standard of care in schizophrenia.